News Buzz: Advaxis (NASDAQ:ADXS), Synthetic Biologics Inc. (NYSEMKT:SYN), KLA-Tencor Corporation (NASDAQ:KLAC), The ExOne Company (NASDAQ:XON), Novavax (NASDAQ:NVAX)

On Tuesday shares of Advaxis, Inc. (NASDAQ:ADXS) closed at $15.39. On 6 April, Advaxis, Inc. (NASDAQ:ADXS) announced that it is entering into a clinical trial collaboration agreement with the Radiation Therapy Oncology Group (RTOG) Foundation to evaluate the safety and efficacy of Advaxis’s lead cancer immunotherapy, ADXS-HPV (ADXS11-001), in a pivotal Phase 2/3 anal cancer trial, which will be run by NRG Oncology. ADXS-HPV is an investigationalLm-LLO immunotherapy bioengineered to generate an immune response to the HPV-associated tumor specific oncogene.

Synthetic Biologics Inc. (NYSEMKT:SYN) in last trading activity fell -3.32% to close at $2.04. Company weekly performance is -10.92% while its quarterly performance stands at 29.11%. Synthetic Biologics Inc. (NYSEMKT:SYN) is -35.75% away from its 52 week high. Synthetic Biologics Inc. (NYSEMKT:SYN) announced that clinical data supporting the development of SYN-004, the Company’s candidate therapy designed to degrade certain beta-lactam intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections, has been selected for presentation during the 115th General Meeting of the American Society of Microbiology (ASM2015) in New Orleans, LA on May 30-June 1.

On last trading day KLA-Tencor Corporation (NASDAQ:KLAC) fell -0.65% to close at $57.76. Its volatility for the week is 1.89% while volatility for the month is 1.93%. KLAC’s sales growth for past 5 years was 14.00% and its EPS growth for past 5 years was 25.60%. KLA-Tencor Corporation (NASDAQ:KLAC) monthly performance is -5.40%. KLA-Tencor Corporation (NASDAQ:KLAC) has been given a “BBB+” credit rating by analysts at Morningstar. The research firm’s “BBB+” rating indicates that the company is a moderate default risk. They also gave their stock a three star rating.

The ExOne Company (NASDAQ:XONE)’s stock on 07 April moved up 0.84% to the closing price of $14.35. Its fifty two weeks range is $13.19 – 48.66. The total market capitalization recorded $208.38M. The ExOne Company (NASDAQ:XONE) monthly performance is 1.56%. On 30 March, , The ExOne Company (NASDAQ:XONE) announced that John A. Baliotti has joined the Company as Director of Marketing and Business Development.

On last trading day Novavax, Inc. (NASDAQ:NVAX) increased 2.56% to close at $8.01. Its volatility for the week is 4.20% while volatility for the month is 4.95%. NVAX’s sales growth for past 5 years was 152.40% and its EPS growth for past 5 years was 4.70%. Novavax, Inc. (NASDAQ:NVAX) monthly performance is -8.98%.On 31 March, Novavax, Inc. (NASDAQ:NVAX) announced the closing of the underwritten public offering priced.

Leave a Reply

Your email address will not be published. Required fields are marked *